NZ767378A - Dosage forms and methods for enantiomerically enriched or pure bupropion - Google Patents

Dosage forms and methods for enantiomerically enriched or pure bupropion

Info

Publication number
NZ767378A
NZ767378A NZ767378A NZ76737819A NZ767378A NZ 767378 A NZ767378 A NZ 767378A NZ 767378 A NZ767378 A NZ 767378A NZ 76737819 A NZ76737819 A NZ 76737819A NZ 767378 A NZ767378 A NZ 767378A
Authority
NZ
New Zealand
Prior art keywords
dosage forms
bupropion
methods
enantiomerically enriched
pure bupropion
Prior art date
Application number
NZ767378A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of NZ767378A publication Critical patent/NZ767378A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ767378A 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion NZ767378A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862634718P 2018-02-23 2018-02-23
US201962794469P 2019-01-18 2019-01-18
US201962809480P 2019-02-22 2019-02-22
PCT/US2019/019445 WO2019165379A1 (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion

Publications (1)

Publication Number Publication Date
NZ767378A true NZ767378A (en) 2024-03-22

Family

ID=67688503

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ767378A NZ767378A (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion

Country Status (19)

Country Link
EP (1) EP3755312A4 (cg-RX-API-DMAC7.html)
JP (3) JP2021513998A (cg-RX-API-DMAC7.html)
KR (3) KR20240091043A (cg-RX-API-DMAC7.html)
CN (2) CN112087999A (cg-RX-API-DMAC7.html)
AU (3) AU2019223187B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020017179A2 (cg-RX-API-DMAC7.html)
CA (1) CA3092076A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002166A1 (cg-RX-API-DMAC7.html)
CR (1) CR20200415A (cg-RX-API-DMAC7.html)
EC (1) ECSP20060179A (cg-RX-API-DMAC7.html)
IL (2) IL276871B2 (cg-RX-API-DMAC7.html)
MA (1) MA51914A (cg-RX-API-DMAC7.html)
MX (2) MX2020008704A (cg-RX-API-DMAC7.html)
MY (1) MY202993A (cg-RX-API-DMAC7.html)
NI (1) NI202000056A (cg-RX-API-DMAC7.html)
NZ (1) NZ767378A (cg-RX-API-DMAC7.html)
PE (1) PE20211752A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202008056SA (cg-RX-API-DMAC7.html)
WO (1) WO2019165379A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3092076A1 (en) * 2018-02-23 2019-08-29 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
CN114423417A (zh) * 2019-09-20 2022-04-29 艾克萨姆治疗公司 用于对映体富集的或纯的安非他酮的剂型和方法
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
KR20250114110A (ko) 2022-11-28 2025-07-28 안테씨프 바이오벤쳐스 투 엘엘씨 약물 활성의 조절제로서의 부프로피온
WO2025259728A1 (en) * 2024-06-13 2025-12-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038502A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
CN1819821B (zh) * 2003-08-08 2010-10-13 拜奥维尔实验室国际股份有限公司 盐酸安非他酮的改良释放片剂
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
EP3981403A1 (en) * 2013-11-05 2022-04-13 Antecip Bioventures II LLC Compositions and methods comprising bupropion or related compounds and dextromethorphan
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
MX2013014166A (es) * 2013-12-03 2015-06-10 Inst De Investigacion En Quimica Aplic S A De C V Enantiomeros activos y sus sales para el tratamiento de la obesidad.
US9732031B2 (en) * 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
CA3092076A1 (en) * 2018-02-23 2019-08-29 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion

Also Published As

Publication number Publication date
CA3092076A1 (en) 2019-08-29
PE20211752A1 (es) 2021-09-06
CN120827545A (zh) 2025-10-24
AU2019223187A1 (en) 2020-09-17
NI202000056A (es) 2021-01-11
IL276871A (en) 2020-10-29
JP2021513998A (ja) 2021-06-03
MY202993A (en) 2024-05-31
KR20240091043A (ko) 2024-06-21
IL276871B2 (en) 2024-11-01
MX2020008704A (es) 2020-12-07
AU2024205858A1 (en) 2024-09-05
IL313368A (en) 2024-08-01
WO2019165379A1 (en) 2019-08-29
ECSP20060179A (es) 2020-12-31
CN112087999A (zh) 2020-12-15
MX2023009281A (es) 2023-08-17
EP3755312A1 (en) 2020-12-30
BR112020017179A2 (pt) 2020-12-22
KR20230075531A (ko) 2023-05-31
AU2022204521A1 (en) 2022-07-21
CL2020002166A1 (es) 2020-10-23
AU2022204521B2 (en) 2024-09-05
JP2024075655A (ja) 2024-06-04
AU2019223187B2 (en) 2022-07-28
CR20200415A (es) 2021-02-03
MA51914A (fr) 2020-12-30
SG11202008056SA (en) 2020-09-29
IL276871B1 (en) 2024-07-01
KR20210003091A (ko) 2021-01-11
EP3755312A4 (en) 2022-03-16
JP2022153638A (ja) 2022-10-12

Similar Documents

Publication Publication Date Title
MY201603A (en) Combination of dextromethorphan and bupropion for treating depression
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2021002321A (es) Nuevos metodos.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
MY199903A (en) Combination therapy with controlled-release cnp agonists
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
MX2021008536A (es) Formulaciones en comprimidos de liberacion modificada que contienen inhibidores de fosfodiesterasa.
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
PH12019502651A1 (en) Use of vibegron to treat overactive bladder
MX2021005967A (es) Formas purificadas de rofecoxib, métodos de fabricación y uso.
MX2022012693A (es) Composicion que comprende metilfolato.
JP2016505050A5 (cg-RX-API-DMAC7.html)
MX2023002350A (es) Composiciones y metodos para mejorar enfermedades y trastornos neurologicos.
NZ751972A (en) Treatment of prurigo nodularis
MX2023006720A (es) Tratamiento con ciclobenzaprina para fibromialgia.
WO2025137652A3 (en) Compositions comprising radiprodil and the use of radiprodil in the treatment of epileptic or neurobehavioral disorders
MX2019003720A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
BR112022010458A2 (pt) Formulação pediátrica de liberação imediata do abridor de canais de potássio ezogabina
CA2469702A1 (en) Darifenacin for use in the treatment of urgency induced by overactive bladder
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
SA522432821B1 (ar) توليفة من ميرتازابين وتيزانيدين للاستخدام في اضطرابات الألم
NZ786429B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
NZ786429A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
MX2025011474A (es) Agentes activos de la metadona y metodos de uso de los mismos

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 FEB 2026 BY BLUE PENGUIN IP LIMITED

Effective date: 20250128

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 FEB 2027 BY CLARIVATE IP SERVICES LIMITED

Effective date: 20260204